Therachon starts a Natural History Study in children with achondroplasia

"Dreambird" is the name of the natural history study that Therachon announced on the 21st June 2018.

Read more ...

BioMarin starts the phase 2 study BMN 111-206 in infants and toddlers

On the 18th June 2018, it was made public that the first patient under 5 years-old was dosed with Vosoritide.

Read more ...

New potential treatment in development for achondroplasia

QED Therapeutics is a biotechnology company focused on precision medicine for FGFR-driven disorders.

Read more ...

4th ALPE Awards

The 4th edition of the ALPE Awards have the following winners:

Read more ...

ALPE participates at the annual convention of the French association APPT

On May 19, 20 and 21, ALPE coordinators

Read more ...

ALPE participates in FDA Advisory Committees meeting on achondroplasia

Two of FDA Advisory Committees: the Pediatric Advisory Committee and the Endocrinologic

Read more ...

Ascendis Pharma starts Phase 1 Trial of TransCon CNP for achondroplasia

On the 8th May 2018, Ascendis Pharma announced the dosing of the first subjects 

Read more ...

ALPE wins the 10th Social Projects of Santander Bank call

The ALPE Foundation was awarded in the 10th Call for Social Projects of the Santander Group.

Read more ...

Request of participation for an international study on Achondroplasia

The Brod Group, is science-based health outcomes research group are looking for participants living in the USA

Read more ...